Summit raises $200M, expands ivonescimab license to LAMEA regions

Summit Therapeutics Inc.

Raised $200M via private placement of 22.2M shares at $9.00/share, a premium to the prior close.
Expanded ivonescimab license territory to Latin America, Middle East, Africa; $15M upfront plus up to $55M milestones.
Net proceeds will fund ivonescimab clinical development and general corporate purposes.
Registration rights agreement filed; resale registration statement expected within 60 days of closing.
Amendment strengthens data-sharing provisions for global ivonescimab trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.